This research laboratory concentrates on developing innovative strategies to combat the growing threat of antibioticresistance. We concentrate on alternatives to antibiotic therapy, such as phage therapy or antivirulence approaches.
Bacteriophages are viruses that lyse and kill bacteria at the end of their life cycles. Their therapeutic potential wasrecognised even before the universal use of antibiotics and is now seen as a possible solution to the problem ofmultiresistant bacteria.
Our research laboratory investigate the efficacy of phage therapy in the treatment of common nosocomial infections, e. g.from Staphylococcus aureus and Pseudomonas auruginosa, using innovative animal models that map real infections. Weemploy these preclinical studies to investigate the efficiency and safety of this therapy, together with the pharmacokineticsand pharmacodynamics.
We have recently developed a rodent model for the pulmonary inflammation associated with respiration – a frequentcomplication of artificial respiration in the clinic. Our results with this model showed that phage therapy was just aseffective as standard antibiotic therapy in controlling the infection (see Prazak et al. 2019 AJRCCM).
- Swiss National Science Foundation; In silico prediction of phage-bacteria infection networks as a tool to implement personalized phage therapy
- Swiss National Science Foundation; Prophylaxis and Treatment of Staphylococcus spp. Intravascular and Extravascular Infections with Phages
- Nebulized bacteriophages for prophylaxis of experimental ventilator-associated pneumonia due to methicillin-resistant staphylococcus aureus. Prazak J, Valente V, Iten M, Grandgirard D, Leib SL, Jakob SM, Haenggi M, Que YA, Cameron DR. Crit Care Med. 2020 Jul;48(7):1042-1046.
- Sustained reduction of catheter-associated bloodstream infections with enhancement of catheter bundle by chlorhexidine dressings over 11 years. Eggimann P, Pagani JL, Dupuis-Lozeron E, Ms BE, Thévenin MJ, Joseph C, Revelly JP, Que YA. Intensive Care Med. 2019 Jun;45(6):823-833.
- Efficacy of newly isolated and highly potent bacteriophages in a mouse model of extensively drug-resistant Acinetobacter baumannii bacteraemia. Leshkasheli L, Kutateladze M, Balarjishvili N, Bolkvadze D, Save J, Oechslin F, Que YA, Resch G. J Glob Antimicrob Resist. 2019 Dec;19:255-261.
- Bacteriophages improve outcomes in experimental staphylococcus aureus ventilator-associated pneumonia. Prazak J, Iten M, Cameron DR, Save J, Grandgirard D, Resch G, Goepfert C, Leib SL, Takala J, Jakob SM, Que YA, Haenggi M. Am J Respir Crit Care Med. 2019 Nov 1;200(9):1126-1133.
- Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Jault P, Leclerc T, Jennes S, Pirnay JP, Que YA, Resch G, Rousseau AF, Ravat F, Carsin H, Le Floch R, Schaal JV, Soler C, Fevre C, Arnaud I, Bretaudeau L, Gabard J. Lancet Infect Dis. 2019 Jan;19(1):35-45.
- Impact of real-time therapeutic drug monitoring on the prescription of antibiotics in burn patients requiring admission to the intensive care unit. Fournier A, Eggimann P, Pantet O, Pagani JL, Dupuis-Lozeron E, Pannatier A, Sadeghipour F, Voirol P, Que YA. Antimicrob Agents Chemother. 2018 Feb 23;62(3):e01818-17. Print 2018 Mar.
- Computational prediction of inter-species relationships through omics data analysis and machine learning. Leite DMC, Brochet X, Resch G, Que YA, Neves A, Peña-Reyes C. BMC Bioinformatics. 2018 Nov 20;19(Suppl 14):420.
- Synergistic interaction between phage therapy and antibiotics clears pseudomonas aeruginosa infection in endocarditis and reduces virulence. Oechslin F, Piccardi P, Mancini S, Gabard J, Moreillon P, Entenza JM, Resch G, Que YA. J Infect Dis. 2017 Mar 1;215(5):703-712.
- Prognostication of mortality in critically ill patients with severe infections. Que YA, Guessous I, Dupuis-Lozeron E, de Oliveira CRA, Oliveira CF, Graf R, Seematter G, Revelly JP, Pagani JL, Liaudet L, Nobre V, Eggimann P. Chest. 2015 Sep;148(3):674-682.
- Pancreatic stone protein as an early biomarker predicting mortality in a prospective cohort of patients with sepsis requiring ICU management. Que YA, Delodder F, Guessous I, Graf R, Bain M, Calandra T, Liaudet L, Eggimann P. Crit Care. 2012 Jul 2;16(4):R114.
- Department of Infectious Diseases, Inselspital, Bern University Hospital (Prof. H. Furrer, MD)
- Institute for Infectious Diseases (IFIK), University of Bern (Prof. S. Leib, MD)
- Department of Fundamental Microbiology, University of Lausanne (Dr. G. Resch, PhD)
- CHUV, University Hospital of Lausanne (Dr. P. Eggimann, Dr. J.-L. Pagani)
- SIB Swiss Institute of Bioinformatics, Yverdon (C. Peña-Reyes)
- Microbiology and Immunobiology, Harvard Medical School, Massachusetts General Hospital Boston, USA (Dr. L. G. Rahme, MD, PhD, MSc, Professor of Surgery)